Ask AI
APP BsAb in MM

CE

APP Perspectives: Safe and Effective Use of Bispecific Antibodies in Multiple Myeloma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 17, 2025

Expiration: May 16, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Danielle Roberts, PA-C, provides an overview of the evolving role of bispecific antibodies in the treatment of relapsed/refractory (R/R) multiple myeloma (MM). The discussion highlights key efficacy data, practical considerations for integrating these agents into current treatment pathways, and real-world strategies for implementing hybrid/outpatient administration models. Insights from her experience at a tertiary academic center emphasize effective care coordination across referral networks and with patients and caregivers to optimize access, safety, and treatment outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

In your discussion with a patient and his wife, which of the following bispecific antibodies would you tell them allows for biweekly dosing immediately after completing step-up dosing?

As you are finalizing safety protocols for bispecific antibodies with your team, which of the following steps is most essential to include in your outpatient workflow to ensure safe management of potential cytokine-release syndrome (CRS)?

How many people with MM do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: